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Osteoarthritic synovial fluid and synovium supernatants
up-regulate tumor necrosis factor receptors on human articular
chondrocytes
By Ginette R. Webb, Carole I. Westacott and Christopher J. Elson
Department of Pathology and Microbiology, University of Bristol, U.K.
Summary
Objective: To determine whether the up-regulation of chondrocyte tumor necrosis factor receptor (TNF-R) expression
in osteoarthritis (OA) is due to molecules released within the OA knee joint.
Design: Non-arthritic (NA) human articular chondrocytes were incubated with normal serum, OA synovial fluid, or
supernatants from either cultured NA or OA synovium, and TNF-R expression measured by flow cytometry.
Results: OA synovial fluid, but not normal serum, significantly up-regulated the proportion of chondrocytes
expressing p55 TNF-R as well as the number of p55 TNF-R/chondrocyte. Similarly, supernatants from OA, but not NA,
synovia significantly up-regulated chondrocyte p55 TNF-R expression. Chondrocyte p75 TNF-R expression was also
significantly increased by some of the OA supernatants but not others, and overall no significant increase was seen.
OA synovium supernatants contained higher concentrations of interleukin-1b (IL-1b) and interleukin-6 (IL-6) than NA
synovium supernatants and neutralizing antibodies to these cytokines either partially or totally abrogated the ability
of the OA supernatants to increase chondrocyte p55 TNF-R expression. Finally, various concentrations of recombinant
human (rh)IL-1b and rhIL-6 up-regulated chondrocyte p55 TNF-R expression.
Conclusion: These results suggest that IL-1 and IL-6 produced by OA synovium contribute to the progression of the
disease by rendering chondrocytes more susceptible to stimulation by catabolic cytokines.
Key words: Osteoarthritis, TNF-receptors, Human articular chondrocytes, IL-1, IL-6.
Introduction
Osteoarthritis (OA) is characterized by focal loss
of articular cartilage. Although the etiology of OA
remains uncertain, it is likely that a number of
separate disease processes converge on a ‘final
common pathway’ culminating in joint damage
[1, 2]. The exact sequence, interrelationship
and cause of the changes leading to such
damage, however, are not well documented. The
integrity of normal cartilage is maintained by
the delicate balance between cytokine-driven
anabolic and catabolic processes. This system
of homeostasis is further ‘fine tuned’ by regulators
of matrix turnover such as tissue inhibitor of
metalloproteases (TIMP) which control the activi-
ties of metalloproteases. In OA the net loss of
proteoglycans and the destruction of the collagen
network within the cartilage is thought to be
caused by a shift in equilibrium toward catabolism.
This theory is borne out by the fact that in
OA cartilage there is an excess of protease
compared with TIMP [3] and that OA synovium
produces more catabolic cytokines, such as
interleukin-1b (IL-1b) [4, 5] and tumor necrosis
factor a (TNFa) [5] than non-arthritic (NA)
synovium.
Previous work has shown that OA cartilage is
more susceptible to the effects of both TNFa [6, 7]
and IL-1b [8] than NA cartilage, and that OA
chondrocytes express more of the receptors
involved in signalling for TNFa (p55) [9] and IL-1
(type I) [10] than NA chondrocytes. The question
thus arises as to what stimulates OA chondrocytes
to express increased levels of these receptors. It is
known that synovial inflammation and increased
subchondral bone activity can predict OA disease
progression [11, 12]. It might therefore be expected
that factors elaborated by these compartments are
those which stimulate OA chondrocytes to express
increased numbers of catabolic cytokine receptors.
The purpose of the current work was to determine
if OA synovial fluid and/or supernatants from
cultured OA synovium up-regulate p55 TNF
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receptor (TNF-R) expression on NA chondrocytes
and if so, to identify the agent(s) responsible.
Materials and Methods
serum and synovial fluid
Normal human serum was obtained from healthy
volunteers at Bristol University and pooled before
use. SF (mean volume 16 2 11 ml, range 4–37) was
aspirated from the knee joint of patients (N = 7; 3
males/4 females, mean age 65.1 2 11.6 years, range
48–80 years) who fulfilled the American College of
Rheumatology criteria for OA, when indicated for
diagnostic or therapeutic reasons. The total white
blood cell count of the SF was 6 · 105 2 12.8 · 105
(range Q105–35 · 105).
cartilage
NA cartilage was obtained from the femoral
heads of patients undergoing hemiarthroplasty
following osteoporotic subcapital fracture of the
femoral neck. In these patients (N = 29; 12 males/17
females, mean age 82 2 7.3 years, range 60–94
years) there was no clinical evidence of arthritis.
The cartilage was macroscopically normal.
chondrocyte isolation
Slices of cartilage, taken less than 6 h postoper-
atively, were removed under sterile conditions
using a scalpel. The cartilage was finely chopped
into cubes (2–3 mm3) and the chondrocytes released
by sequential enzymatic digestion as previously
described [9]. The resulting digest was filtered
(40 mm, Falcon) to remove any debris and the
chondrocytes washed in HAMS F12 medium
supplemented with 2 mm l-glutamine, 100 U/ml
penicillin, 100 mg/ml streptomycin, 25 mm HEPES
and 10% foetal calf serum (FCS) (complete HAMS).
The viability of the chondrocytes as assessed by
trypan blue exclusion was 95.2 2 3.2% (range
90–99). To allow TNF-R to return to pre-treatment
levels [13, 14], chondrocytes were rested for 16 h
(37° C, 5% CO2) in flasks coated with 2% agarose
(Type VII, Sigma) [9].
culture of chondrocytes with sf
Following overnight (16 h) incubation the chon-
drocytes were harvested and washed by centrifu-
gation in complete HAMS (1000 rpm, 7 min).
Chondrocytes (5 · 105/ml) were further incubated
with complete HAMS or complete HAMS sup-
plemented with 50% SF. As a control, chondro-
cytes were also cultured in the presence of 50%
normal serum. All incubations were carried out in
agarose-coated 24-well plates (Falcon) (24 h, 37° C,
5% CO2), after which time chondrocytes were
removed and prepared for staining.
synovium
NA synovium was obtained from the hip joint of
patients (N = 2F, aged 74 and 82 years) undergoing
hemiarthroplasty following osteoporotic subcapi-
tal fracture of the femoral neck and from one
normal knee joint [1 (male), age 67 years] less than
48 h post-mortem. As a further control, tissue was
obtained from within the medullary canal of one
patient [1 (male), age 25 years] at the time of
removal of an intramedullary nail inserted 18
months previously for treatment of tibial shaft
fracture. Such tissue has previously been used as
normal material where the fracture was soundly
united and there was no evidence of osteolysis [4].
Fig. 1. Effect of normal human serum and OA synovial
fluid on (a) the proportion of NA chondrocytes
expressing p55 TNF-R and (b) the relative number of p55
TNF-R/chondrocyte. Chondrocytes were cultured in
either normal human serum (Q) or OA SF (q) for 24 h
and stained for TNF-R.
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Clinical evidence of arthritis was absent in all NA
patients. Synovium was obtained from OA patients
(N = 6, 4 males/2 females, mean age 68.8 2 3.4,
range 65–74 years) who fulfilled the American
College of Rheumatology criteria, undergoing
surgery for total knee replacement. One patient,
undergoing bilateral total knee replacement,
provided a specimen of synovium from each
knee.
synovium culture
Synovium was aseptically removed from the
femoral heads and knee joints using scissors,
weighed and cut into small pieces (2–3 mm3). The
synovium was washed in phosphate-buffered saline
(PBS) and cultured in RPMI supplemented with
2 mm l-glutamine, 100 U/ml penicillin, 100 mg/ml
streptomycin, and 25 mm HEPES and 5% FCS
Fig. 2. Effect of synovium supernatants on (a) the proportion of NA chondrocytes expressing p55 TNF-R and (b) the
relative number of p55 TNF-R/chondrocyte. Chondrocytes were cultured in (i) medium or medium containing 25% NA
synovium supernatant (NA = 4) or (ii) medium or medium containing 25% OA synovium supernatant (OA = 7) for 24 h
and stained for TNF-R expression. Each point represents the mean value of experiments performed on chondrocytes
prepared from between two and five different cartilage donors. Each line joins the values obtained for chondrocytes
cultured in the presence and absence of one synovium supernatant. The heavy bars indicate the mean value for each
group.
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(0.2 g of tissue/1 ml RPMI). After incubation
for 24 h (37° C, 5% CO2) the supernatant was
aspirated from the tissue, filtered (40 mm, Falcon),
centrifuged (4000 rpm, 10 min) to remove any
fat and cellular debris and stored in aliquots at
- 70° C.
culture of chondrocytes with synovium
supernatant
Chondrocytes were harvested, washed by cen-
trifugation in RPMI supplemented with 5% FCS
(1000 rpm, 7 min) and cultured in RPMI or RPMI
Fig. 3. Effect of synovium supernatants on (a) the proportion of NA chondrocytes expressing p75 TNF-R and (b) the
relative number of p75 TNF-R/chondrocyte. Chondrocytes were cultured in (i) medium or medium containing 25% NA
synovium supernatant (NA = 4) or (ii) medium or medium containing 25% OA synovium supernatant (OA = 7) for 24 h
and stained for TNF-R expression. Each point represents the mean value of experiments performed on chondrocytes
prepared from between two and five different cartilage donors. Each line joins the values obtained for chondrocytes
cultured in the presence and absence of one synovium supernatant. The heavy bars indicate the mean value for each
group.
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supplemented with 25% synovium supernatant.
After incubation (37° C, 5% CO2, 24 h) cells were
removed and prepared for staining. All incubations
were carried out in agarose-coated 24-well plates
(Falcon). Each synovium supernatant was tested
on chondrocytes prepared from between two and
five different cartilage donors.
measurement of IL-1b in synovium
supernatants
IL-1b was measured in supernatants by a
commercially available enzyme-linked immunosor-
bent assay (ELISA) (Biotrak, Amersham). The kit
was assessed for use with culture supernatants. A
subset of supernatants was serially diluted in the
assay to test linearity of the response and
determine optimal dilution (neat–1/5). Linearity
was obtained in the IL-1b assay. Spiking exper-
iments were performed and the recovery of added
IL-1b was 89.5% (range 80.7–98.1).
measurement of il-6 in synovium supernatants
IL-6 was measured as previously described [15]
and the measurements were subjected to PROBIT
analysis [16] due to non-linearity.
incubation with neutralizing antibodies
To determine the possible identity of the
up-regulatory factor(s), chondrocytes were cul-
tured in the presence of 25% synovium super-
natants containing either normal goat serum or
goat anti-serum directed against either IL-1a and
IL-1b (NIBSC, 1/250: 1/250) or IL-6 (NIBSC, 1/750).
In three experiments sufficient IL-6 (R&D Systems,
10 ng/ml) to neutralize the effects of the antibody
was added to chondrocytes cultured with 25%
synovium supernatant and anti-IL-6. Similarly in
three experiments sufficient IL-1b (NIBSC, 1 ng/
ml) to neutralize the effects of the antibody was
added to chondrocytes cultured with 25% syn-
ovium supernatant and anti-IL-1a and b. After
incubation (37° C, 5% CO2, 24 h) chondrocytes were
removed and prepared for staining.
In some experiments chondrocytes were incu-
bated with RPMI alone or in the presence of
varying concentrations of either rhIL-1b or rhIL-6.
After incubation (37° C, 5% CO2, 24 h) chondro-
cytes were removed and prepared for staining.
cell preparation and staining
The chondrocytes were washed twice in 2 m
sodium chloride/20 mm HEPES buffer (pH 7.4) and
Fig. 4. Ability of neutralizing antibodies to IL-1a and
IL-1b or anti-IL-6 to inhibit the up-regulatory effect of
synovium supernatants on (a) the proportion of
chondrocytes expressing p55 TNF-R and (b) the relative
number of p55 TNF-R/chondrocyte. NA chondrocytes
were incubated in medium alone (Q) or medium
containing 25% OA synovium supernatant ( ) or
medium containing 25% synovium supernatant and
either mixtures of neutralizing antibodies to IL-1a and
IL-b (q) or anti-IL-6 (;). The chondrocytes were stained
for TNF-R after 24 h.
once in 2 m sodium chloride/20 mm sodium acetate
(pH 4) to remove any bound ligand [9]. The
viability of the chondrocytes was assessed again
and was 75 2 14%. U937 cells, a monocytic cell line
known to express TNF-R [17], were used as a
positive control; Raji cells, a B-cell line reported
not to express TNF-R [18], was used to determine
nonspecific binding [19]. The chondrocytes and
control cells were stained for p55 and p75 TNF-R
expression using non-cross-reacting antibodies [19]
and analysed by flow cytometry as previously
described [9]. Briefly, chondrocytes and control
cells (5 · 105/25 ml) were incubated (45 min, 4° C)
with mouse monoclonal antibodies (kind gift of Dr
M. Brockhaus, Hoffman La Roche, Basel) to either
the p55 receptor (htr9), the p75 receptor (utr1), or
with IgG1 isotype control (Becton Dickinson). All
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Table I
Effect of normal goat serum on upregulation of p55 TNF-R expression by chondrocytes
cultured in the presence of an OA synovium supernatant (s/n)
Proportion of chondrocytes p55 TNF-R number/
Culture conditions expressing p55 TNF-R (%) chondrocyte
RPMI alone 5.4 2 2.0 614 2 405
25% synovium s/n 7.7 2 0.3 1933 2 289
25% synovium s/n 8.9 2 1.9 1936 2 269
+ normal goat serum
N2[
cells were washed and incubated (15 min, 4° C)
with goat anti-mouse IgG conjugated to fluor-
escein-isothiocyanate (Dako). The cells were then
washed and resuspended in 250 ml PBS/0.25%
formaldehyde before analysis (FACScan, Becton
Dickinson). Comparison was made between cells
stained with specific monoclonal antibodies and
cells from the same population stained with the
appropriate isotype control. Results were calcu-
lated by determining the shift in fluorescence of
the test population compared with control
and expressed as the proportion of positive cells
in the population analysed (5000 cells).
The reproducibility of the calculation of the
percentage expression, the co-efficient of variance
(CV), was 8.9 2 0.8% and the limit of detection
2%.
To estimate the number of receptors/cell, beads
exhibiting various numbers of mouse IgG mol-
ecules (Dako, Qifi-kit) were incubated, at the same
time as cells, with fluorescein-labelled goat
anti-mouse IgG. A standard curve of mean
fluorescence intensity against antigen density was
constructed using the beads. The net fluorescence
intensity of the chondrocytes run at the same
setting was measured. The relative receptor
number on the chondrocytes (which is directly
proportional to the antigen density) was calcu-
lated from the standard curve. The reproducibility
of the estimation of receptor number/chondrocyte
(CV) was 8.7 2 1.0% and the limit of detection 100
TNF-R/chondrocyte.
statistical analysis
The Student’s paired t-test was used to analyse
the differences between stimulated and unstimu-
lated NA chondrocyte populations. Differences
between OA and NA synovium supernatants and
differences between supernatants tested on differ-
ent chondrocyte populations were analysed by
two-way analysis of variance (ANOVA).
Results
effects of oa sf on na chondrocyte tnf-r
expression
NA chondrocytes were incubated with either a
pool of normal serum or SF from OA patients and
the proportion of chondrocytes expressing p55
TNF-R and the numbers of p55 TNF-R/chondrocyte
measured. The results for seven different SF are
illustrated in Fig. 1(a) and (b). p55 TNF-R
expression was increased by all the OA SFs as
compared with normal serum. Both the proportion
of chondrocytes expressing p55 TNF-R and the
number of p55 TNF-R/chondrocyte were signifi-
cantly increased by OA SF (P Q 0.014 and
P Q 0.005, respectively) as compared with chondro-
cytes incubated with normal serum. It should be
noted that the chondrocyte TNF-R expression was
unaffected by normal serum and therefore rep-
resents the basal level. The proportion of chondro-
cytes expressing p55 TNF-R after culture in
medium was 4.5 2 6.1% and in normal serum
Table II
Effect of IL-6 on the neutralizing ability of anti-IL-6 on chondrocytes cultured in the
presence of an OA synovium supernatant (s/n)
Proportion of chondrocytes p55 TNF-R number/
Culture conditions expressing p55 TNF-R (%) chondrocyte
RPMI alone 2.0 2 2.8 164 2 232
25% synovium s/n 7.6 2 0.5 2394 2 361
25% synovium s/n 2.9 2 4.1 71 2 120
+ anti-IL-6
25% synovium s/n 8.3 2 0.8 2915 2 66
+ anti-IL-6 + IL-6
N2[
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Table III
Effect of IL-1b on the neutralizing ability of anti-IL-1a/b on chondrocytes cultured in the
presence of an OA synovium supernatant (s/n)
Proportion of chondrocytes p55 TNF-R number/
Culture conditions expressing p55 TNF-R (%) chondrocyte
RPMI alone 2 100
25% synovium s/n 9.0 2 1.2 2849 2 787
25% synovium s/n 2 100
+ anti-IL-1
25% synovium s/n 9.2 2 0.9 3223 2 325
+ anti-IL-1 + IL-1
N2[
5.8 2 5.5% (N = 5, P = 0.23). The number of p55
TNF-R/chondrocyte in medium was 830 2 1166 and
in normal serum 1491 2 1362 (N = 5, P = 0.42). The
proportion of chondrocytes expressing p75 TNF-R
and the number of p75 TNF-R/chondrocyte was
below the detection limit before and after
incubation with OA SF.
effect of synovium supernatant on na
chondrocyte tnf-r expression
Experiments were performed to determine
whether the TNF-R up-regulating activity present
in OA SF could be due to release of products by
cells in diseased synovium. NA chondrocytes were
incubated with medium alone or with supernatants
from cultured NA synovium and the effect on
TNF-R expression measured. As can be seen from
Fig. 2 (a)i, (b)i, NA synovium supernatants had no
significant effect on either the proportion of
chondrocytes expressing p55 TNF-R or on the
number of p55 TNF-R/chondrocyte as compared
with medium alone. Similar experiments were
performed with medium and supernatants from
OA synovia. Supernatants from OA synovia
significantly increased the proportion of NA
chondrocytes expressing the p55 TNF-R (P Q 0.001)
[Fig. 2(a)ii] and up-regulated the number of
p55 TNF-R/chondrocyte (P Q 0.001) [Fig. 2(b)ii]
as compared with chondrocytes cultured in
medium alone. It can also be seen from Fig. 2 that
p55 TNF-R expression varied on chondrocytes
cultured in medium alone. However, the effect
of OA synovium supernatants was consistent.
For example, the proportion of chondrocytes
expressing p55 TNF-R isolated from three different
individuals and incubated with medium was
Q2, Q2 and 4.9%, respectively, while after culture
with a synovium supernatant from one patient
the proportion was 14.8, 17.1 and 13.2%, respect-
ively. Similarly the numbers of p55 TNF-R on the
three chondrocyte preparations incubated in
medium was Q100, Q100 and 724 and with the
synovium supernatant 2695, 1914, 2754, respect-
ively.
It can be seen from Fig. 3 that one out of four NA
synovium supernatants and three out of seven OA
synovium supernatants significantly increased
both the proportion of chondrocytes expressing
p75 TNF-R and the number of p75 TNF-R
/chondrocyte. However, overall both NA and OA
synovium supernatants had no significant effect on
either the proportion of chondrocytes expressing
p75 TNF-R or on the number of p75 TNF-R/chon-
drocyte as compared with medium alone.
effect of neutralizing antibodies on the
up-regulation of tnf-r expression by synovium
supernatants
Both IL-1b [20] and IL-6 [21] are known to
up-regulate TNF-R on various cell types. These
observations led us to consider that these
cytokines may contribute to the effects of OA
synovium supernatants on chondrocyte TNF-R
expression. As a first step towards examining this
possibility, IL-1b and IL-6 concentrations were
measured in the supernatants. The concentration
of IL-1b in the four NA synovium supernatants was
7.7 2 7 pg/ml (range R3–17) and in the seven OA
supernatants was 344 2 242 pg/ml (range 48–691).
The concentration of IL-6 in NA supernatants was
0.8 2 0.8 ng/ml (range R0.1–1.6) and in the OA
supernatants was 6.4 2 4.5 ng/ml (range 0.12–15.2).
Next, neutralizing antibodies to IL-1 or IL-6 were
added to supernatants at the time of incubation
with chondrocytes and the effects on TNF-R
measured. The results are recorded in Fig. 4(a and
b). It is evident that both mixtures of anti-IL-1a and
b, and anti-IL-6 significantly (P Q 0.001 and
P Q 0.001, respectively) decreased the proportion
of chondrocytes expressing the p55 TNF-R as
compared with chondrocytes incubated in the
presence of OA synovium supernatant alone
[Fig. 4(a)]. Similarly, both mixtures of anti-IL-1a
and b, and anti-IL-6 significantly (P Q 0.001 and
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P Q 0.001, respectively) decreased the number of
p55 TNF-R/chondrocyte [Fig. 4(b)].
In concurrent experiments, chondrocytes were
incubated with supernatant (25%) or supernatant
containing normal goat serum (1/250 dilution) and
TNF-R expression measured. From Table I it can
be seen that normal goat serum failed to inhibit the
effects of synovium supernatant on either
the proportion of cells expressing p55 TNF-R or the
number of p55 TNF-R/chondrocyte.
The specificity of the anti-IL-6 and anti-IL-1a and
b serum was also tested by attempting to reverse
the effects of the antibody by addition of
exogenous rhIL-6 or rhIL-1b. Chondrocytes were
cultured in medium alone, medium containing a
synovium supernatant (25%), medium containing a
synovium supernatant (25%) and either anti-IL-6
or anti-IL-6 and IL-6 (10 ng/ml), and TNF-R
expression measured. Table II shows that the
addition of rhIL-6 restored the proportion of cells
expressing p55 TNF-R and the number of p55
TNF-R/chondrocyte to the levels seen on chondro-
cytes incubated in the presence of 25% synovium
supernatant alone. Analogous experiments carried
out with anti-IL-1a/b and rhIL-1b gave a similar
result (Table III).
Finally, the effects of rhIL-1b and rhIL-6 on
chondrocyte p55 TNF-R expression were measured.
NA chondrocytes were incubated with increasing
concentrations of either rhIL-1b or rhIL-6. Fig. 5
shows that IL-1b increased p55 TNF-R expression
at concentrations of 1 and 10 pg/ml but not at
100 pg/ml, while IL-6 increased p55 TNF-R ex-
pression at concentrations from 100 pg/ml to
10 ng/ml but not at 20 ng/ml or above. It should be
noted that no significant difference in cell viability
was found between chondrocytes cultured in the
presence of low or high concentrations of either
cytokine.
Discussion
These results show that OA SF has the capacity
to up-regulate p55 TNF-R expression on NA human
articular chondrocytes. Both the proportion of
chondrocytes expressing p55 TNF-R and the
number of p55 TNF-R/chondrocyte were increased.
It may be argued that a two- to threefold increase
in p55 TNF-R expression is unlikely to have an
affect on cartilage degradation. However, recent
work in our laboratory showed that the suscepti-
bility of cartilage explants to TNFa, as judged by
glycosaminoglycan (GAG) loss, is directly related
to chondrocyte p55, but not p75, TNF-R expression
[6]. Moreover, a twofold increase in chondrocyte
p55 TNF-R expression, on average, resulted in a
two- to threefold increase in GAG release. Taken
together these results suggests that the increase in
chondrocyte p55 TNF-R reported here is biologi-
cally relevant.
Evidence that p55 TNF-R enhancing factors are
produced locally in OA joints comes from the
finding that supernatants from OA synovia
significantly enhanced the proportion of chondro-
cytes expressing p55 TNF-R as well as the number
of p55 TNF-R/chondrocyte. By contrast, super-
natants from NA synovium had no effect on
chondrocyte TNF-R expression. Synovial cells can
produce a variety of pro- and anti-inflammatory
cytokines and the concentrations of some are
increased in disease [4, 5, 22–24]. It would appear
Fig. 5. Effect of IL-1b (a) and IL-6 (b) on chondrocyte p55
TNF-R expression. The proportion of chondrocytes
expressing p55 TNF-R is represented by (......) and p55
TNF-R number/chondrocyte by (——). The
means 2 s.e.m. of three experiments performed on
chondrocytes from different NA cartilage donors are
shown.
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likely therefore that one or more of the latter are
responsible for the effects seen.
What is the identity of the p55 TNF-R enhancing
agent? The results point towards IL-1 and IL-6.
This contention is supported by a number of
observations. First, both cytokines were present in
the OA synovium supernatants at higher concen-
trations than in the NA supernatants. Second,
neutralization experiments demonstrated that the
up-regulating effect of OA synovium supernatant
on p55 TNF-R expression were inhibited by goat
antisera to IL-1a/b and IL-6 but not normal goat
serum. The specificity of the anti-sera was also
confirmed by the fact that their corresponding
recombinant cytokines reversed the inhibitory
effects of the anti-sera. Third, chondrocyte TNF-R
expression was increased by low concentrations of
rhIL-1b and rhIL-6. By contrast high concen-
trations of rhIL-1b, comparable with those de-
tected in some OA synovium supernatants, were
without effect. It could be argued, therefore, that
the results are contradictory. However, the
supernatants were diluted for culture with chon-
drocytes thus bringing the concentration of IL-1b
in most supernatants into the range at which
rhIL-1b enhanced chondrocyte TNF-R expression.
Moreover, inhibitory molecules produced by
synovium, such as soluble IL-1R [25] and IL-1R
antagonist [26], should both be present in the
supernatants and would thereby reduce the
biological activity of the IL-1b present. Finally, as
already discussed, IL-1b may act together with
other molecules such as IL-1a and IL-6 to enhance
chondrocyte TNF-R expression.
Expression of p55 TNF-R and p75 TNF-R on a
number of cell types is independently regulated
[27, 28]. The results suggest that the same is true of
chondrocyte TNF-Rs. OA SF enhanced chondro-
cyte p55 but not p75 TNF-R expression. Addition-
ally, most synovium supernatants up-regulated p55
TNF-Rs whereas only some up-regulated p75
TNF-Rs.
Experimental models of OA have implicated
both TNFa and its receptors as well as IL-6 in the
disease process. For example, a generalized
intensification of chondrocytic TNF-R staining
with reduced metachromasia indicative of carti-
lage loss was noted in canine OA induced by
cruciate ligament section [29]. In the same model,
others reported elevated levels of IL-6 and TNFa in
SF from the operated as compared with the sham
operated joint. Moreover, SF TNFa concentrations
correlated with proteoglycan loss from cartilage
[30]. It is also accepted that IL-1 and TNFa could
be involved in the OA process by virtue of their
capacity to stimulate chondrocytes to degrade
cartilage matrix and/or inhibit matrix synthesis.
However, less attention has been paid to the
possibility that the susceptibility of chondrocytes
to catabolic stimuli affects the osteoarthritic
process. This work shows that IL-1 and IL-6
produced by OA synovium increase p55 TNF-R
expression which is known to result in increased
susceptibility to TNFa-induced cartilage degra-
dation [6]. These results thus advance the
hypothesis that catabolic cytokines and their
receptors have a role in the progression of OA.
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